Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heavy ion beam offers new hope for tough Head-and-Neck cancers

NCT ID NCT04185974

Disease control Sponsor: University Hospital Heidelberg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a precise type of radiation called carbon ion re-radiotherapy for people whose head-and-neck cancer has returned or worsened after standard treatment. About 72 adults who cannot have surgery will receive this therapy to see if it causes fewer severe side effects and helps control the cancer longer. The goal is to improve safety and quality of life compared to standard re-radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2020

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Locally recurrent / progressive head-and-neck cancer after initial radiation therapy * Microscopic or macroscopic tumor after salvage surgery * Indication for re-irradiation * Completed wound healing after surgical intervention * Karnofsky-Performance-Score ≥ 60 * Age ≥ 18 years * Written informed consent (must be available before enrolment in the trial) * Ability of subject to understand character and individual consequences of the trial * For women with childbearing potential, (and men) adequate contraception * Submission of previous radiotherapy records Exclusion Criteria: * Re-irradiation of malignancy in the larynx * Diagnosed plasmocytoma, sarcoma or chordoma * Previous re-irradiation in-field * Time interval \< 6 months after initial radiotherapy * Distant metastases (except pulmonary metastases) * Patients who have not recovered from acute toxicities of prior therapies * Refusal of the patients to take part in the study * Pregnant or lactating women * Known carcinoma \<5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy * Participation in another clinical study or observation period of competing trials, respectively

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced head and neck cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Philips University Marburg

    RECRUITING

    Marburg, 35037, Germany

  • University Hospital of Heidelberg, Radiation Oncology

    RECRUITING

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.